Ruibo (Hangzhou) Pharmaceutical Technology Co., Ltd. announced a placement of common shares for gross proceeds of CNY 50,000,000 on November 15, 2023. The transaction will include participation from returning investor, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. The transaction has been approved at the 39th meeting of the 7th board of directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. CNY 49,000,000 will be included in the capital surplus and CNY 1,000,000 will be included in the registered capital increasing it from CNY 91,970,802.920 to CNY 92,970,802.920.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.36 CNY | -1.45% | +1.49% | -32.42% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.42% | 2.04B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 603456 Stock
- News Zhejiang Jiuzhou Pharmaceutical Co., Ltd
- Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd